Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van Den Bosch, Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, Atul Deodhar, Désirée Van Der Heijde, Xiaoqi Li, Fangyi Zhao, Clinton C. Bertram, Gaia Gallo, Hilde Carlier, Lianne S. Gensler

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds